Sushrut S. Waikar
Boston University
399 Papers
669 Citations
Sushrut S. Waikar is an academic researcher from Boston University. The author has contributed to research in topics: Medicine & Kidney disease. The author has an hindex of 56, co-authored 244 publications. Previous affiliations of Sushrut S. Waikar include Brigham and Women's Hospital & Washington University in St. Louis.
Chat about Author
Papers
Not All Controls Are Made Equal: Comparison of Single-Cell Gene Expression in Human Kidney Reference Samples
Rajasree Menon,Edgar A. Otto,Jeffrey B Hodgin,Abhijit S. Naik,E. Woodle,John R. Sedor,Sylvia E. Rosas,Sushrut S. Waikar,Markus Bitzer,Petter Bjornstad,M. Kretzler +10 more
TL;DR: The gut microbiota plays a significant role in CKD progression through alterations in its composition and the production of uremic toxins. These toxins damage the intestinal epithelial barrier, increase gut permeability, and facilitate the translocation of bacteria and endotoxins into the bloodstream, leading to endotoxemia and inflammation.
Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI).
Peter A. McCullough,Josée Bouchard,Sushrut S. Waikar,Edward D. Siew,Zoltan H. Endre,Stuart L. Goldstein,Jay L. Koyner,Etienne Macedo,Kent Doi,Salvatore Di Somma,Andrew Lewington,Ravi Thadhani,Raj Chakravarthi,Can Ice,Mark D. Okusa,Jacques Duranteau,Peter Doran,Li Yang,Bertrand L. Jaber,Shane Meehan,John A. Kellum,Michael Haase,Patrick T. Murray,Dinna N. Cruz,Alan S. Maisel,Sean M. Bagshaw,Lakhmir S. Chawla,Ravindra L. Mehta,Andrew D. Shaw,Claudio Ronco +29 more
TL;DR: The ADQI (Acute Dialysis Quality Initiative) had its Ninth Consensus Conference dedicated to synthesis and formulation of the existing literature on biomarkers for the detection of acute kidney injury in a variety of settings.
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
Ajay K. Singh,Allison Blackorby,Borut Cizman,Kevin Carroll,Alexander R. Cobitz,Rich Davies,Vivekanand Jha,Vivekanand Jha,Vivekanand Jha,Kirsten L. Johansen,Renato D. Lopes,Lata Kler,Iain C. Macdougall,John J.V. McMurray,Amy Meadowcroft,Gregorio T. Obrador,Vlado Perkovic,Scott D. Solomon,Christoph Wanner,Sushrut S. Waikar,David C. Wheeler,Andrzej Wiecek +21 more
TL;DR: The ASCEND-D clinical trial as mentioned in this paper evaluated the efficacy and safety of daprodustat compared with epoetin alfa or darbepoencodal alfa in the treatment of patients with anaemia with chronic kidney disease (CKD G5D).
Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness
David E. Leaf,Kirolos A. Jacob,Anand Srivastava,Margaret E. Chen,Marta Christov,Marta Christov,Harald Jüppner,Venkata S. Sabbisetti,Aline Martin,Myles Wolf,Sushrut S. Waikar +10 more
TL;DR: Elevated FGF23 levels measured in the urine or plasma may be a promising novel biomarker of AKI, death, and other adverse outcomes in critically ill patients.
Trans-ethnic genome-wide association study of blood metabolites in the chronic renal insufficiency cohort (CRIC) study.
Eugene P. Rhee,Aditya Surapaneni,Zihe Zheng,Linda Zhou,Diptavo Dutta,Dan E. Arking,Jingning Zhang,ThuyVy Duong,Nilanjan Chatterjee,Sheng-dong Luo,Pascal Schlosser,Rupal Mehta,Sushrut S. Waikar,Santosh L. Saraf,Tanika N. Kelly,L. Lee Hamm,Panduranga S. Rao,Anna V. Mathew,Chi-yuan Hsu,Afshin Parsa,Ramachandran S. Vasan,Paul L. Kimmel,Clary B. Clish,Josef Coresh,Harold I. Feldman,Morgan E. Grams +25 more
TL;DR: The authors conducted a GWAS of 537 blood metabolites measured in the Chronic Renal Insufficiency Cohort (CRIC) Study, with separate analyses in 822 White and 687 Black participants, and trans-ethnic meta-analysis was applied to improve fine-mapping of potential causal variants.